1. OP screening involves 1) A good history and examination to asses risk factors and h/o fracture and examination including BMI and loss of height, reduced space between lower ribs and pelvis, spinal tenderness. 2) Look for secondary causes 3) Addictions particularly tobacco use 4) Medications 5) Biochemistry including calcium, ALP 6) Bone mineral density (BMD) assessment within six months of initiation of glucocorticoid treatment. Most widely used tool is Dual-energy x-ray absorptiometry (DXA) thought newer techniques like pDXA (peripheral DXA), Quantitative Computerised Tomography (QCT) and peripheral QCT are available but needs validation and are costlier. 7) Biochemical biomarkers like C telopeptide, free deoxypyridinoline may independently predict fracture risk but are not routinely used Fracture Risk Assessment Tool (FRAX) developed by University of Sheffield, estimates 10-year probability of hip and major OP fracture (hip, clinical spine, proximal humerus, or forearm) between 40-90 years using clinical risk factors with/without femoral neck BMD. [2] Besides age, gender, weight, height, it includes risk factors as defined in Box 1 where only Rheumatoid Arthritis is taken in rheumatic diseases, steroid use has been defined as ≥ 5mg for 3 or more months. There are however insufficient data to develop prediction tools for younger adults and children. Although the greatest relative risk of fracture is in individuals with osteoporosis (OP), the absolute number of fractures in those with BMD T-scores in the low bone mass (osteopenia) range is the same or greater than in those with T-scores in the osteoporosis range, as more individuals belong to the latter category. At times BMD may give us a fall sense of hope and some patients who need preventive therapy may be missed. 
Rheumatic Diseases
Various studies have looked at the prevalence of osteoporosis in rheumatic disease. [4, 5] Prevalence and some of the associated risk factors have been mentioned in Table 1 . It is important to remember that osteoarthritis, syndesmophytes, new bone formation, atherosclerosis may falsely increase BMD measurement. [6, 7] Management strategy should include FRAX score calculation and risk stratification and the use of OP medications accordingly. Moderate to high risk patients should be treated with OP medications even if steroids are not used. ( Table 2 and Figure 1) GIOP (Glucocorticoid induced Osteoporosis) Long-term glucocorticoid therapy causes osteoporotic fractures in about 10-12% of treated adult patients and 30-40% of them have radiographic evidence of vertebral fractures, in view of higher effects of steroids on trabecular bone [8, 9] Daily doses of ≤5 mg prednisolone have been shown to increase fracture risk by ~20%, rising to 60% for doses of ≥20 mg per day. [7, 10] Fracture risk is highest particularly within first the 3-6 months and correlates with cumulative dose and daily dose. [10] Still the preventive care is suboptimal and less than a quarter undergo OP assessment and often the therapy is instituted once a fracture occurs.
Whom to Treat?
In GIOP, the terms 'prevention' and 'treatment' distinguish between the initiation of antiosteoporosis intervention at the start of glucocorticoid therapy or after >3 months, respectively.
Prevention:
Depending on risk stratification, all adults irrespective of age, not of childbearing age or childbearing age but not planning a pregnancy during treatment, with moderate to high risk as defined in Table 2 , should receive oral Bisphosphonate. Second line therapies include IV bisphosphonate, teriparatide, denosumab and raloxifene (for post-menopausal women only) in that order except in women of childbearing potential where teriparatide is preferred over oral bisphosphonate. IV bisphosphonate and denosumab lack safety data in pregnancy and hence should be used only in high risk patients whereas raloxifene is not recommended. Some authorities do no rate bisphosphonates over teriparatide due to lack of head to head comparisons. Denosumab, though not a first line therapy, but is a good alternative particularly in patients with renal failure. Some experts recommend upfront teriparatide in patients with T-score < -3.5 or T-score of -2.5 or below plus a fragility fracture. Romosozumab, sclerostin inhibitor, is another new emerging therapy yet to find a place in guidelines. Refer to table 3 for dosing, side effects and monitoring.
Other essential recommendations including for those with low risk of fracture are 1) Daily calcium and vitamin D 1,000-1,200 mg and 600-800 IU respectively 2) Lifestyle modifications like cessation of smoking, limiting alcohol intake to 1-2/day, 3) Balanced diet and weight and daily exercises. Figure 1 summarises the prevention strategy and follow up treatment [11] In case of moderate to high risk, continue oral Bisphosphonate for ten years and Zoledronic acid for five years. There is no concept of drug holiday in such cases. Besides GCs, Methotrexate, Cyclophosphamide, heparin, oral anticoagulants, anti-convulsant are some of the medications which have been implicated in OP.
4)
CKD, Chronic Kidney Disease; GERD, Gastro-esophageal reflux disease; GFR, Glomerular filtration rate; s.c, subcutaneous Osteoporosis is a potentially preventable complication which needs to be taken care of by a rheumatologist considering an increasing prevalence of OP in rheumatic diseases. Good control of disease and hence inflammation, minimising steroid use, emphasis on dietary and lifestyle modifications, calcium and vitamin D supplementation and use of OP medications when indicated will help in reducing this complication. "Prevention is always better than cure! Action is better than procrastination."
Summary

1.
Osteoporosis is a common but neglected issue, amenable to therapy or prevention in patients with rheumatic diseases particularly on steroids. 2. 10-12% patients on steroid suffer from fracture or 30-50% have radiological evidence of vertebral fracture with maximum loss occurring in 3-6 months. 3. Do not forget secondary causes which further increase the risk of osteoporosis. 4. All patients with rheumatic diseases, age 40 years or more, and children with risk factors should undergo BMD within six months of initiation of glucocorticoid. 5. FRAX score, with correction for steroid dose, can be used in patients aged  40 years for fracture risk prediction with/without BMD. (https//www.shef.ac.uk/FRAX/tool.jsp) 6. Treatment should be started for those falling in moderate to high risk. 7. There is no role of follow up BMD adults population on treatment unless there are risk factors and/or development of fracture despite  18 months of therapy or poor adherence/compliance. 8. There is no concept of drug holiday at end of 3-5 years if there is moderate to high risk and therapy should be continued for additional 3-5 years. 9. Upfront Teriparatide maybe considered in T-score < -3.5 or T-score of -2.5 or below plus a fragility fracture or a contra-indication for bisphosphonate except pregnancy
